The remarkable clinical activity of chimeric antigen receptor (CAR) therapies in B cell and
plasma cell malignancies has validated the use of this therapeutic class for liquid cancers …

Immunotherapy has been a remarkable clinical advancement in the treatment of cancer. T
cells are pivotal to the efficacy of current cancer immunotherapies, including immune …

Background Immunotherapy with chimeric antigen receptor (CAR)–expressing T cells that
target the disialoganglioside GD2 expressed on tumor cells may be a therapeutic option for …

Cancers are highly complex diseases that are characterized by not only the overgrowth of
malignant cells but also an altered immune response. The inhibition and reprogramming of …

Chimeric antigen receptor (CAR) therapy has had a transformative effect on the treatment of
haematologic malignancies,,,,–, but it has shown limited efficacy against solid tumours. Solid …

Therapies with genetically modified T cells that express chimeric antigen receptors (CARs)
specific for CD19 or B cell maturation antigen (BCMA) are approved to treat certain B cell …

Approximately 60% of patients with large B cell lymphoma treated with chimeric antigen
receptor (CAR) T cell therapies targeting CD19 experience disease progression, and …

Although chimeric antigen receptor (CAR) T cells have altered the treatment landscape for B
cell malignancies, the risk of on-target, off-tumour toxicity has hampered their development …

Despite impressive progress, more than 50% of patients treated with CD19-targeting
chimeric antigen receptor T cells (CAR19) experience progressive disease. Ten of 16 …

This Review discusses the major advances and changes made over the past 3 years to our
understanding of chimeric antigen receptor (CAR) T cell efficacy and safety. Recently, the …